Erythrocyte pyruvate kinase activation in red cell disorders
Current Opinion in Hematology, 2023•journals.lww.com
Preclinical and clinical evidence indicate that pyruvate kinase activators represent new
therapeutic option in hemoglobinopathies or SCD. Other red cell disorders such as
hereditary spherocytosis or hereditary anaemias characterized by defective erythropoiesis
might represent additional areas to investigate the therapeutic impact of pyruvate kinase
activators.
therapeutic option in hemoglobinopathies or SCD. Other red cell disorders such as
hereditary spherocytosis or hereditary anaemias characterized by defective erythropoiesis
might represent additional areas to investigate the therapeutic impact of pyruvate kinase
activators.
Summary
Preclinical and clinical evidence indicate that pyruvate kinase activators represent new therapeutic option in hemoglobinopathies or SCD. Other red cell disorders such as hereditary spherocytosis or hereditary anaemias characterized by defective erythropoiesis might represent additional areas to investigate the therapeutic impact of pyruvate kinase activators.
Lippincott Williams & Wilkins